NR 566 Week 8 Final Review
-
$29.00
| Institution | NR 566 Advanced Pharmacology for Care of the Family |
| Contributor | Jessica Stock |
- Question: Antacids MOA
- Question: which antacids have the highest absolute neutrophil count (ANC)?
- Question: what do calcium containing antacids needs for absorption?
- Question: Antacid Indications
- Question: Monitoring after given antiviral for flu
- Question: 1st line therapy for uncomplicated UTI
- Question: what causes ophthalmia neonatorum
- Question: patient education for albendazole & mebendazole
- Question: patient education for ivermectin
- Question: patient education for ibendazole
- Question: Aminopenicillins Drugs
- Question: Fluoroquinolone older drugs
- Question: Fluoroquinolones new drugs
- Question: Macrobid indication
- Question: the most common cause of Traveler's diarrhea
- Question: PUD stepped-approach algorithm
- Question: what causes most diarrhea?
- Question: symptomatic treatment for viral URIs
- Question: 1st lines therapy for acute otitis media (AOM) & sinusitis
- Question: When aminopenicillins are combined with beta-lactamase inhibitors
- Question: beta-lactamase inhibitors that can be combined with aminopenicillins
- Question: Penicillinase-resistant penicillins drugs
- Question: Penicillinase-resistant penicillins active against
- Question: Anti-pseudomonal penicillin drugs
- Question: Anti-pseudomonal penicillins active against
- Question: 1st generation cephalosporins drugs
- Question: 1st generation cephalosporins active against
- Question: 2nd generation cephalosporins drugs
- Question: 3rd generation cephalosporins drugs
- Question: 4th generation cephalosporins drugs
- Question: 2nd generation cephalosporins active against
- Question: 3rd generation cephalosporins active against
- Question: 4th generation cephalosporins active against primarily
- Question: which cephalosporins are best against gram (+) organisms
- Question: ADR for cephalosporins
- Question: indications for cephalosporins
- Question: Pharmacodynamics of cephalosporins
- Question: fluoroquinolones active against
- Question: Pharmacodynamics of fluoroquinolines
- Question: Fluoroquinolones indications
- Question: black box warning for fluoroquinolones
- Question: macrolide drugs
- Question: Pharmacodynamics of macrolides
- Question: macrolides are active against
- Question: Macrolide indications
- Question: Macrolide drug interactions
- Question: sulfonamide drugs
- Question: sulfonamide drugs active against
- Question: sulfonamide indications
- Question: Pharmacodynamics of sulfonamides
- Question: Trimethoprim mechanism of action
- Question: Trimethoprim active against
- Question: Nitrofurantoin mechanism of action
- Question: Nitrofurantoin active against
- Question: sulfonamide drug interactions
- Question: nitrofurantoin drug interactions
- Question: sulfonamide ADR
- Question: AIDS and sulfonamides
- Question: Nitrofurantoin ADR
- Question: ADR with G6PD and sulfonamides
- Question: blood dyscrasias and sulfonamides
- Question: Bactrim indications
- Question: Bactrim drug interactions
- Question: Clindamycin indications
- Question: clindamycin ADRs
- Question: Clindamycin mechanism of action
- Question: prophylaxis treatment for ophthalmia neonatorum
- Question: most common UTI orgamisms
- Question: 1st line therapy for uncomplicated UTI in adult woman
- Question: Characteristics of Complicated UTI
- Question: Recurrent UTI prevention
- Question: indications for referral to Urologist
- Question: Antimycobacterial drugs
- Question: antimycobacterial mechanism of action
- Question: active TB first phase (initiation phase) drugs
- Question: active TB 2nd phase (continuation) drugs
- Question: antiviral drugs: nucleoside analogues
- Question: Acyclovir (Zovirax) indications
- Question: Valacyclovir (Valtrex) indications
- Question: famciclovir indications
- Question: Ganciclovir indications
- Question: Ribavirn indications
- Question: antiviral (nucleoside analogues) mechanism of action
- Question: Antivirals for Influenza (neuraminidase inhibitors)
- Question: Antiviral Neuraminidase inhibitor mechanism of action
- Question: Antifungal (Antimycotics) classes
- Question: Azoles - Triazoles drugs
- Question: Polyene Macrolides drugs
- Question: Allylamines Drugs
- Question: Nuclear acid synthesis inhibitor drugs
- Question: Azoles mechanism of action
- Question: Polyene Macrolides MOA
- Question: Flucytosine mechanism of action
- Question: Ketoconazole mechanism of action
- Question: fluconazole & posaconazole mechanism of action
- Question: itraconazole & voriconazole mechanism of action
- Question: Clotrimazole indications
- Question: Ketoconazole indications
- Question: Fluconazole indications
- Question: Itraconazole (Sporanox) indications
- Question: Posaconazole (Noxafil) indications
- Question: Voriconazole (Vfend) indications
- Question: Terbinafine (Lamisil) indications
- Question: Amphotericin B
- Question: Griseofulvin indications
- Question: Miconazole (Monistat) indications
- Question: Antifungal monitoring
- Question: Anthelmintic (antiparasitic) drugs
- Question: Benzimidazoles MOA
- Question: Pyrantel MOA
- Question: Ivermectin MOA
- Question: Mebendazole (Vermox) indications
- Question: Nematodes
- Question: Cestodes
- Question: Trematodes
- Question: Albendazole (Albenza) indication
- Question: Pyrantel indications
- Question: Ivermectin (Stromectol) indications
- Question: Metronidazole (Flagyl), nitazoxanide, & tinidazole
- Question: Metronidazole indications
- Question: Nitazoxanide (Alinia) indications
- Question: Tinidazole (Tindamax) indications
- Question: Metronidazole MOA
- Question: Nitazoxanide (Alinia) MOA
- Question: tinidazole (Tindamax): MOA
- Question: Metronidazole drug interactions
- Question: bacterial vaginosis treatment
- Question: Diagnosis of bacterial vaginosis
- Question: cardinal symptoms of chronic bronchitis which indicate need for antibiotic
- Question: Tinea corporis (ringworm) treatment
- Question: Tinea pedis (athletes foot) treatment
- Question: Tinea Capitis (Scalp Ringworm) treatment
- Question: Tinea Cruris (Jock Itch) Treatment
- Question: onychomycosis
- Question: 1st line treatment for primary and secondary skin infections
- Question: medications and dose to eradicate nasal MRSA
- Question: treatment for acute sinusitis
- Question: What is the 1st line therapy for GERD?
- Question: Antacid ADRs
- Question: Antacids: Drug Interactions
- Question: antacid patient education
- Question: lifestyle changed to prevent GERD symptoms
- Question: Antidiarrheal classes
- Question: Absorbent antidiarrheals drugs
- Question: opiate antidiarrheals drugs
- Question: anticholinergic antidiarrheals drugs
- Question: Kaolin MOA
- Question: pectin MOA
- Question: Bismuth Subsalicylate MOA
- Question: Lomotil (diphenoxylate/atropine) MOA
- Question: motofen (difenoxin/atropine) MOA
- Question: Loperamide (Imodium) MOA
- Question: Crofelemer (Fulyzaq) indication
- Question: antidiarrheal precautions/contraindications
- Question: antidiarrheal ADRs
- Question: antidiarrheal drug interactions
- Question: Laxative classes
- Question: laxative stimulant
- Question: Osmotic laxatives
- Question: Bulk producing laxative
- Question: Lubricant laxatives
- Question: surfactant laxative
- Question: hyperosmolar laxative
- Question: Chloride channel activators drugs
- Question: Opioid receptor antagonists drugs
- Question: laxative 1st line therapy
- Question: Laxatives are contraindicated in
- Question: laxative precautions
- Question: Cytoprotective agents
- Question: Clinical Pearl for polyethylene glycol electrolyte solution
- Question: Sucralfate (Carafate)
- Question: Misprostol (Cytotec)
- Question: Cytoprotective Agents Side Effects
- Question: Misoprostol precautions
- Question: antiemetic classes
- Question: Antihistamines antiemetics
- Question: Phenothiazines antiemetics
- Question: Cannaboids antiemetics
- Question: 5-HT3 receptor antagonist antiemetics
- Question: Anticholinergic antiemetics
- Question: P/neurokinin 1 receptor antagonist antiemetic
- Question: Mics antiemetic
- Question: monitoring of long term use of promethazine
- Question: antihistamine antiemetic precautions/ contraindications
- Question: phenothiazine precautions/contraindications
- Question: dronabinol precautions/contraindications
- Question: 5-HT3 antagonists antiemetic precuations/contraindications
- Question: Scopalamine (Transderm Scop) precuations/contraindications
- Question: Aprepitant (Emend) precautions/contraindications
- Question: Phenothiazines ADR
- Promethazine (Phenergan) ADR
- H2 receptor antagonists MOA
- H2 receptor antagonists drugsCimetidine (Tagamet)
- H2 receptor antagonists precuations/contraindications
- H2 receptor antagonists ADR
- H2 receptor antagonists drug inteactions
- H2 receptor antagonists monitoring
- H2 receptor antagonists patient education
- Prokinetic drugs
- prokinetic MOA
- black box warning for metoclopramide (Reglan)
- Metoclopramide (Reglan) pecaution/contraindications
- Metoclopramide (Reglan) ADR
- Metoclopramide (Reglan) drug interactions
- Proton Pump Inhibitors (PPIs) MOA
- Proton Pump Inhibitors (PPIs) indications
- Proton Pump Inhibitors (PPIs)
- PPI Precautions/Contraindications
- PPI ADRs
- PPI drug interactions
- PPI black box warning
- PPI monitoring
- GERD management
- PPI therapy for mod to severe GERD
- PPI step up or step down approach
- 1st line triple therapy for H. Pylori
- 2nd line therapy for H. Pylori with PCN allergy
- 2nd line therapy or rescue therapy for H. Pylori
- IBS with constipation treatment
- Traveler's Diarrhea Treatment
- High risk destinations for traveler's diarrhea
- Intermediate risk destinations for traveler's diarrhea
- other causes of traveler's diarrhea
- Bacterostatic
- bacteriocidal
- Bacteriostatic drugs
- Bactericidal drugs
- anti-microbial resistance
- subclasses of Beta-lactams PCNS
- Pharmacodynamics of Beta-lactam PCNs
- 1st line therapy for Strep pharyngitis.
- 1st line therapy for all bites
- Natural PCN's, Drugs
- Natural PCNs active against
- Aminopenicillins active against
| Instituition / Term | |
| Term | Year 2022 |
| Institution | NR 566 Advanced Pharmacology for Care of the Family |
| Contributor | Jessica Stock |
